Background. For glycemic control in diabetic patients on dialysis it was unclear what level of glycated albumin (GA) was associated with the lowest mortality and GA's utility. Accordingly, we examined the difference in association between GA and hemoglobin A1c (HbA1c) with 1-year mortality in a cohort of the Japanese Society for Dialysis Therapy. Methods. We examined 84 282 patients with prevalent diabetes who were on maintenance hemodialysis (HD) (female 30.3%; mean age 67.3 6 11.2 years; mean dialysis vintage 6.4 6 4.5 years). Of them, 22 441 had both GA and HbA1c. We followed these for a year, 2013-14, using Cox regression to calculate adjusted hazard ratios (HRs) and 95% confidence limits for 1-year mortality after adjusting for potential confounders such as baseline age, sex, smoking and diabetes type. Results. One-year mortality was lowest in diabetic HD patients who had GA levels of 15.6-18.2% and HbA1c levels of 5.8-6.3%. The associations were linear or J-shaped for GA and U-shaped for HbA1c. Adjusted HRs were significantly higher in patients with GA <12.5% and GA !22.9%. This trend flattened in elderly patients, those with higher hemoglobin or those with prior cardiovascular disease. In addition, the C-statistics, Harrell's C and category-free net reclassification improvement to predict 1-year mortality were better when GA was added to the model than when HbA1c was added.
I N T R O D U C T I O N
Intensive glycemic control is essential for preventing progression of diabetic microvascular complications such as retinopathy and nephropathy, with hemoglobin A1c (HbA1c), generally, the gold standard for glycemic control [1] . However, hemodialysis (HD) patients' red blood cells (RBCs) live for a shorter time; blood loss may occur and erythropoietinstimulating agents (ESA) to treat renal anemia may boost the percentage of immature RBCs. So patients with end-stage renal disease (ESRD) may have a more complicated relationship between HbA1c and average blood glucose than do those with normal renal function, their glycemic control being underestimated [2] [3] [4] . Moreover, patients who have renal insufficiency or are on HD face risk of increased hypoglycemia from decreased clearance of insulin and oral hypoglycemic agents, impaired renal gluconeogenesis and other causes [5, 6] . Ceasing hypoglycemic agents because of frequent hypoglycemic episodes is called the 'burnt-out diabetes phenomenon' [5, 7, 8] . The Kidney Disease Outcome Quality Initiative (KDOQI) Clinical Practice Guideline for Diabetes-and other observational studies-suggests a higher risk of death in HD patients with HbA1c levels <6.5 and >8.0% [6, 9, 10] .
Glycated albumin (GA) has recently been suggested as a preferred glycemic marker in HD patients, reflecting glycemic control during, approximately, the preceding 2 weeks [11, 12] . Although albuminuria, cirrhosis, thyroid dysfunction and smoking can impact GA, it remains a useful glycemic marker in HD patients because GA is unaffected by the longevity of RBCs or ESA administration, and albuminuria typically falls with HD patients' lower glomerular filtration rates, potentially minimizing albuminuria's effect [1, 4] . Even so, the 2012 KDOQI Clinical Practice Guideline for Diabetes does not recommended GA as a first-line tool for assessing glycemic control [6] . The best practice guide for diabetic patients on HD (2012) by the Japanese Society for Dialysis Therapy (JSDT) suggested GA levels <20.0% as tentative targets for glycemic control in HD patients without a history of cardiovascular disease (CVD) and <24.0% for those with such history. It also called for more study to definitively determine the target value for HD patients' GA [4] . Accordingly, to establish the association between glycemic control and mortality-focusing on the ability to predict mortality with GA-we studied a nationwide registry of HD patients in Japan.
M A T E R I A L S A N D M E T H O D S

Database creation
The JSDT has been conducting annual questionnaire surveys of dialysis facilities throughout Japan since 1968, compiling a computer-based registry since 1983. The details were described previously [13] [14] [15] [16] [17] [18] . The standard analysis file, which was prepared by the Committee of Renal Data Registry for the present study (JRDR_SAF-2016-001), covered 314 438 patients dialyzed at 4268 facilities in the 2013 survey [19] and 320 448 patients at 4330 facilities in 2014 [20] . Those diagnosed with diabetes and/ or receiving diabetic medications-and receiving maintenance dialysis on 31 December 2013-were followed for 1 year. We excluded patients who lacked a diabetes history; had been dialyzed fewer than three times a week (or <2 h per treatment); had received peritoneal dialysis; had undergone organ transplantation; whose records covering date of birth, dialysis initiation or outcome were incomplete or who were considered outliers ( Figure 1) .
The JRDR contains demographic data. For instance, it contains data on age, sex, dialysis vintage, height, body weight postdialysis, hemodiafiltration, smoking, vascular complications (cerebral infarction, cerebral hemorrhage, myocardial infarction or amputation), diabetes type, hypoglycemic agents, clinic types and antihypertensive agents. It also contains data on laboratory examinations like HbA1c (National Glycohemoglobin Standardization Program), GA, albumin, hemoglobin, calcium, phosphate, intact parathyroid hormone (iPTH), high-density lipoprotein, C-reactive protein (CRP), dialysis treatment adequacy (Kt/V) and normalized protein catabolic rate. Detailed information about JRDR data has been given previously [14, 21] . We defined cardiovascular death as that due to chronic heart failure, pulmonary edema, ischemic heart disease [including acute myocardial infarction (AMI), that is, died within 30 days after onset], arrhythmia, valvular heart diseases, endocarditis and other cardiac diseases; we defined cerebrovascular death as subarachnoid hemorrhages, intracerebral hemorrhages, cerebral infarctions and other brain diseases. We sent questionnaires to all Japanese dialysis facilities and collected data at the end of the year.
Measurement of GA and HbA1c
The JRDR was designed as a questionnaire-based observational study, thus a central laboratory was not involved; all measurements were routinely carried out at each center. However, all GA measurements were made by enzymatic method using the same Lucica GA-L kit (Asahi Kasei Pharma, Tokyo, Japan) [22] and all HbA1c measurements were standardized following Japan Diabetes Society guidelines [23] . HbA1c measurements in Japanese laboratories are 70.1% high-performance liquid chromatography, 18.4% latex agglutination immunoassay and 11.5% enzymatic, with 1.44-1.77% coefficient of variation among methods [24] .
Statistical methods
We summarized data using proportions, with means (6SD) as appropriate. We analyzed categorical variables with the chi-square test and compared continuous variables using the t-test as appropriate. And we refined laboratory data: height 120-200 cm, body weight 20-150 kg, albumin 1.0-5.0 g/dL, CRP <30 mg/dL, hemoglobin 5.0-20.0 g/dL, iPTH <3000 mg/dL, HbA1c 4.0-15.0%, GA 10.0-50.0% and Kt/V 0.5-2.5. We also Glycated albumin, HbA1c and 1-year mortality in HD patients normalized protein catabolic rate (0.3-2.0) [25] . If whole parathyroid hormone (PTH) measured parathyroid level, we converted it to iPTH, multiplying by 1.7 [26] . The primary analyses were conducted using patients who had both GA and HbA1c (n ¼ 22 441), with multiple imputation that incorporated multivariate normal regression for missing laboratory data with 10 nonmissing replacements imputed for every missing value. The percentage missing in each variable is shown in Supplementary data, Table S1 . GA and HbA1c were categorized using deciles of patients who had both GA and HbA1c. The cutoffs for GA were 15 Predictability of 1-year mortality in patients with both GA and HbA1c when the baseline clinical model included either or both was assessed by C-statistics, Harrell's C-index, categoryfree net reclassification improvement (cfNRI) and integrated discrimination improvement (IDI). The clinical model included age, sex, dialysis vintage, dialysis modalities, BMI, history of CVDs, type of diabetes, smoking history, hemoglobin, serum albumin, CRP and high-density cholesterol.
To make our results comparable with previous reports, we recategorized GA by þ2.5 and HbA1c by þ0.5 and ran the same analyses using patients who had either GA (n ¼ 45 249) or HbA1c (n ¼ 61 474). After Cox regressions, we used the cubic spline with five knots approach to arrive at figures of hazard ratios (HRs) with continuous GA and HbA1c values.
Toranomon Hospital's ethics committee approved this protocol and procedures fully adhered to the Declaration of Helsinki. The study was registered with the University Hospital Medical Information Network (UMIN000018641). All analyses were carried out using Stata SE version 14.1 (StataCorp, College Station, TX, USA). Table S2 ). Total person-years at risk in the primary dataset (n ¼ 22 441) was 21 307.01 with 1886 deaths and 79 579.04 with 7337 deaths in the entire cohort (n ¼ 84 282). When we divided patients into 10 groups by GA level, the lowest mortality rate was observed in patients who had GA levels of 17.1-18.2% (Table 1 ). We excluded 32 634 patients due to lack of GA or HbA1c. These tended to be elderly, had lower BMI and/or had less use of hypertensive or hypoglycemic agents. In addition, they had lower 1-year survival and a higher proportion of cardiovascular death compared with the glycemic measurements (Supplementary data, Table S3 ).
R E S U L T S
Study characteristics
All-cause mortality by serum GA level at enrollment
In the 22 441 patients with both GA and HbA1c, after adjusting for age, sex, vintage, dialysis modality, vascular complications, smoking, type of diabetes, BMI, antihypertensive agents use, hypoglycemic agents use, facility type, Kt/V, normalized protein catabolic rate, hemoglobin, albumin, CRP, high-density cholesterol, calcium, phosphate and PTH at baseline, the relationship between the adjusted HRs and GA was J-shaped, with that of GA level 15.6-18.2% lowest ( Figure 2 and Table 2 ). Adjusted HRs of all-cause 1-year mortality were significantly higher in patients with GA !22.9%. We then preformed subgroup analyses of the primary dataset stratified by tertiles of hemoglobin, albumin and age, plus use of hypoglycemic agents and presence or absence of CVD history-defined as having experienced myocardial infarction, stroke or amputation. All subgroup analyses were adjusted for the variables detailed above in the section 'Statistical methods'. In patients with higher hemoglobin, the elderly or those with prior CVD history, the mortality trend flattened, especially in those with worse glycemic control (Figure 3 ; Supplementary data, Table S4 ). Moreover, mortality was notably higher in patients with lower GA if they were hypoglycemic agents users with a lower hemoglobin level. Since the HRs of patients with GA <15.6% (n ¼ 4099) were slightly higher than of those with GA 15.6-18.2% [HR 1.07 (95% CL 0.82-1.39)], we next analyzed adjusted HRs among 45 249 patients with low GA as a sensitivity analysis. The HRs of patients with baseline GA <12.5 (n ¼ 317) and 12.5-15 (n ¼ 2443) [referent 15.0-17.5 (n ¼ 7541)] were, respectively, 2.53 (95% CL 1.10-5.80) and 1.06 (95% CL 0.68-1.66) (Supplementary data, Figure S1 and Table S5 ). Adjusted HRs were significantly higher in patients with GA <12.5% and GA !22.5%. To check the association of continuous GA and 1-year mortality while capturing the proper functional form, spline regression with five knots was performed in patients with GA (n ¼ 45 249). Although our primary analysis showed that GA association was linear or J-shaped, our additional analysis also suggested the possibility of worse mortality in patients with very low GA levels, especially for patients with lower albumin, with HbA1c (%) Glycated albumin, HbA1c and 1-year mortality in HD patients hypoglycemic agents use or without prior CVD history (Supplementary data, Figure S1 ).
All-cause mortality by serum HbA1c level at enrollment
After adjusting for the same variables, the relationship between the adjusted HRs and HbA1c was also U-shaped, with that of HbA1c 5.8-6.3% lowest ( Figure 2B Table 2 ). The adjusted HRs were significantly worse in patients with HbA1c <5.3% and !7.6%, with HbA1c 5.8-6.3% lowest. Again, we performed subgroup analyses of the primary dataset as detailed above. As with GA analyses, in patients with higher hemoglobin, the elderly or those who had prior CVD history, the adjusted mortality trend flattened-especially in patients with higher glycemic control (Supplementary data, Figure S1 ). To check the association of continuous GA and 1-year mortality while capturing the proper functional form, spline regression was performed with five knots in patients with HbA1c (n ¼ 61 474). The results were very similar in each analysis, with a low of HbA1c of 6.0%. The U-shaped trend became clearer in patients who had lower albumin (Alb <3.5 g/dL), had used hypoglycemic agents or who lacked a prior CVD history (Figure 3) .
The correlation coefficient between HbA1c and GA was 0.6083, although it was lower in subgroups with lower albumin, higher age, a CVD history and without hypoglycemic agents use (Supplementary data, Table S6 ).
Predictability of 1-year mortality with GA and HbA1c added
Next, we compared the predictability of 1-year mortality among patients with both GA and HbA1c when adding GA or HbA1c; for this we used deciles of glycemic control Table 3) . Similar trends were observed in patients with antihypoglycemic agents. In the GA model, cfNRI and IDI were, respectively, 0.0895 (95% CL À0.0014-0.1804; P ¼ 0.05) and 0.0012 (0.000-0.0024; P ¼ 0.05). This suggests that 1-year mortality predictability is improved by adding GA or HbA1c to the model.
D I S C U S S I O N
In this large-scale study we found that 1-year mortality was lowest in patients in the group with GA 15.6-18.2% and the group with HbA1c 5.8-6.3% regardless of albumin, hemoglobin, age, hypoglycemic agents use or prior CVD history, suggesting that All-cause mortality (hazard ratios) divided by deciles of (A) GA levels and (B) HbA1c levels (n ¼ 22 441). Adjusted variables include age, sex, vintage, modality, BMI, smoking, type of diabetes, hypertensive agents use, types of glycemic control agent use (insulin/ dipeptidyl peptidase-4/other hyperglycemic agents), hemoglobin, albumin, CRP, PTH, calcium, phosphate, high-density cholesterol, Kt/V, normalized protein catabolic rate, history of CVD (stroke/ myocardial infarction/amputation) and type of dialysis center. Subgroup analyses of all-cause mortality (hazard ratios) divided by deciles of (A) glycemic albumin levels and (B) hemoglobin A1c levels (n ¼ 22 441). Alb, albumin; Hb, hemoglobin; CVD, history cardiovascular diseases (stroke/myocardial infarction/amputation). Adjusted variables: age, sex, vintage, modality, BMI, smoking, types of diabetes, hypertensive agents use, types of hypoglycemic agents use (insulin/ DPP4/OHA), hemoglobin, albumin, C-reactive protein, parathyroid hormone, calcium, phosphate, high density cholesterol, Kt/V, normalized protein catabolic rate, prior CVD history, and type of dialysis center.
the GA target level for HD patients should exceed the normal reference range, 11.9-15.8% [1] , a phenomenon similar to the higher HbA1c target level for HD patients for patients in general [6] . Previously, increased mortality was reported in diabetic HD patients with higher levels of GA [27, 28] , the upper limit of GA's glycemic control; this resulted in the current clinical guideline for glycemic control in Japan, which suggests GA levels of <20.0% as a tentative target for glycemic control in patients without any CVD and levels of <24.0% for those with a CVD history [4] . Our primary analyses supported the linear mortality trend in GA. However, although more concrete evidence is needed, we should be careful with patients who have a very low GA level (e.g. GA <12.5%) since our subanalyses of the larger population who evidenced only GA showed significantly worse 1-year mortality in patients with GA <12.5%. The U-shaped associations are not unique to HD patients. For example, the position statement of the American Diabetes Association for non-HD patients recommends less stringent HbA1c goals in patients with a history of severe hypoglycemia and advanced micro-or macrovascular complications [29] . Models including GA and/or HbA1c predicted 1-year mortality better, suggesting the importance of measuring GA and HbA1c. Since this is an association study, we would not place too much emphasis on this result: recent studies have suggested better utility of longitudinal measurement of GA for hospitalization and survival in diabetic HD patients [30, 31] . Overall, models including GA predicted better than those with HbA1c, although differences were generally slight, probably due to the short observation period. Recently, 'burnt-out diabetes' has become widely noticed in diabetic patients undergoing maintenance HD [5, 8, 32] . Potential contributors to this phenomenon include decreased drug clearance, lower gluconeogenesis, protein-energy wasting, dialysis effect and low HbA1c confounded by anemia. In our study, 47.1% had HbA1c <6.0%-similar to results of the recent Japanese study [33] -whereas with GA <12.5% and <15.0%, prevalence was, respectively, only 0.7% and 6.1%. This suggests the importance of the effect of anemia when assessing burnt-out diabetes by HbA1c. Yet with the threshold of HbA1c set from <6.0% to <5.5% in our Japanese population, 26.0% of patients had burnt-out diabetes, still higher than their proportion defined by GA level. Defining burnt-out diabetes by using HbA1c and GA requires further study. Moreover, analyses of the discrepancy between these two indicators of glycemic control in HD patients may provide some hint as to the mechanism of this phenomenon.
This study has several limitations. First, as with any annual survey, our database contains a one-point estimate of glycemic control per year, rendering analyses with time-averaged GA levels within a year impossible. However, some previous largedatabase reports showed similar mortality among initial and time-averaged HbA1c groups [9, 34] . Second, we lacked information about the use of ESA. But since it was reported that GA was unaffected by the life span of RBCs or ESA administration [35] [36] [37] , the effect of ESA in the GA-mortality association may be small and hence may not change our results. Finally, given the nature of questionnaire-based studies, some selection biases could be present. For example, facilities that are not interested in glycemic control may not routinely check diabetic HD patients' GA or HbA1c, or may check infrequently. We found 23.9% lacking data on GA or HbA1c, and their mortality rates may differ from our results. Although our survey covers most of the Japanese facilities [19] , the incidence of death in the 84 282 patients we analyzed was higher than in the patients excluded due to missing data on glycemic control (n ¼ 32 634) (9.2 versus 11.4 deaths/100 person-years; P < 0.01). Thus patients whose GA or HbA1c is measured clinically may receive better care than others (Supplementary data, Table S3 ). A random and mandatory survey is necessary to clarify this type of selection bias. As for the frequency of GA monitoring, the best practice guide for diabetic HD patients (as noted, published in Japan in 2012) stated that for all diabetic HD patients, GA level should be monitored at least monthly [4] . Hopefully this means that the lack of data due to infrequency of glycemic control measurement may be minimized. In addition, our definition of CVD did not include patients who underwent coronary artery bypass grafting, coronary interventions or carotid endarterectomy. Therefore our definition may exclude patients in an early phase of CVD and/or those who received more intensive medical care, which may cause selection bias in our subgroup analyses. Understanding factors associated with mortality remains a priority in clinical care for diabetic HD patients. Glycemic control is definitely a most important point for diabetic patients, including those with ESRD. Recent reports have debated the utility of HbA1c and GA as glycemic markers in HD patients [1, 38] . Although GA has a greater potential for accuracy of glycemic control than HbA1c, since evidence showing a GA-mortality association in HD patients is limited, concluding the superiority of GA as a mortality marker is premature, although some data suggest that GA was less affected by anemia, etc., than HbA1c. Again, as with any observational study, our results could not say whether using GA provides better prevention of diabetic macrovascular complications. Nevertheless, this study does provide some evidence for the utility of GA in predicting 1-year mortality in a large-scale cohort of maintenance HD patients.
In conclusion, we found that there was a linear or J-shaped association between GA level and 1-year mortality in diabetic HD patients, with the lowest mortality in those whose GA level was 15.6-18.2% regardless of serum albumin or prior CVD. Also, the lowest 1-year mortality was found in patients with HbA1c levels of 5.8-6.3%. Since our data now show only 1-year mortality, we must wait several years to ascertain GA's ability to predict HD patients' multiyear mortality. Firm conclusions or guidelines for GA control should not be presumed from these data.
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